12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Subcutaneous Orencia abatacept regulatory update

FDA approved an sBLA for a subcutaneous formulation of Orencia abatacept from Bristol-Myers to treat moderate to...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >